NCT06318481CompletedPhase 3
TADCLOT- a Double Blind Randomized Controlled Trial
Twice a Day Clopidogrel vs Ticagrelor in Reducing Major Cardiac Events in Patients With Acute STEMI Undergoing Primary Percutaneous Intervention- TADCLOT- a Double Blind Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 10 Jul 2025
Brief summary (registry, in English)
Compare the safety and efficacy of a twice-daily Clopidogrel regimen vs. Ticagrelor in reducing major adverse events in patients undergoing primary PCI in a double-blind randomized controlled trial.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 2200 (actual)
- First submitted
- 7 Mar 2024
- Start date
- Feb 2024
- Primary completion date
- Feb 2025
- Lead sponsor
- National Institute of Cardiovascular Diseases, Pakistan
- Diseases
- Coronary artery disease
- NCT number
- NCT06318481
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 2200
- From Feb 2024 to the primary completion date, Feb 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Thrombolytic therapy \<24 hours
Other illness
- Patients with STEMI secondary to stent thrombosis or index event being a complication of PCI within 30 days
- Moderate to severe hepatic impairment
Lab values
- Platelet count \< 100,000 and Hemoglobin \<10 gm/dl
Other
- Pregnancy or lactation
- Patients with advanced CKD and those on hemodialysis
- Recent ICH or major bleed requiring transfusion
- Inability to give informed consent
- Participation in another study
- Inability to fulfill protocol (living outside the city etc.)
Who the study is looking for
- ST-segment elevation ≥1 mm in ≥ 2 contiguous ECG leads or New or presumably New left bundle branch block
- Age ≥18 years
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Institute of Cardiovascular Diseases Coordinator of this site? Confirm its status | Karachi | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.